Skip to content
Review Open access

Intense pulsed light as a multi-target intervention paradigm for refractory ocular surface diseases: a review

Sep 2026 · Eye and Vision · Vol 13 · 0 citations · 125 references
Medicine

TL;DR

Overall, IPL therapy represents a promising but evolving treatment strategy for refractory OSDs, and current knowledge regarding the proposed mechanisms, clinical applications, treatment protocols, limitations, and future directions are summarized.

Abstract

Ocular surface diseases (OSDs) are a heterogeneous group of disorders characterized by overlapping inflammatory, vascular, microbial, neuroimmune, and meibomian gland abnormalities that contribute to the onset and persistence of ocular surface symptoms and signs. Conventional symptom-directed therapies do not adequately alleviate refractory meibomian gland dysfunction, Demodex-associated blepharitis, ocular rosacea, recurrent chalazion, and allergic conjunctivitis. Recent evidence suggests that these conditions may share convergent pathological features, including chronic inflammation, abnormal lid-margin vascularity, and microbial or parasitic imbalance. Intense pulsed light (IPL), which was initially used for vascular and inflammatory disorders in dermatology, has emerged as a potential physical therapy that acts through several proposed mechanisms in patients with selected refractory OSDs, including photothermal liquefaction of inspissated meibum, coagulation of abnormal vessels, reduction of Demodex and microbial burden, modulation of inflammatory responses, and possible effects on neuroimmune signaling; however, these mechanisms remain incompletely established. Case series and clinical studies have reported improvements in ocular symptoms, tear film stability, meibomian gland function and drainage, lid-margin inflammation, and chalazion or lesion resolution, particularly when IPL is combined with meibomian gland expression or other adjunctive therapies. However, treatment responses vary across disease phenotypes and standardized treatment parameters, long-term safety data, and high-quality randomized controlled trials remain limited. Anatomical factors, disease severity, glandular structure, and inflammatory status may also influence therapeutic outcomes. Overall, IPL therapy represents a promising but evolving treatment strategy for refractory OSDs. This review summarizes the current knowledge regarding the proposed mechanisms, clinical applications, treatment protocols, limitations, and future directions and provides updated perspectives for the rational use of IPL in OSD management.

Read PDF

Similar papers

Review Open access Oct 2026

Microneedle-based drug delivery for inflammatory and immune-mediated ocular diseases: current applications and future perspectives

ABSTRACT Inflammatory and immune-mediated ocular diseases encompass a spectrum of conditions that arise from dysregulated immune-inflammatory responses marked by a chronic clinical course, a propensity for relapse, and a tendency to cause significant ocular tissue damage, which can lead to profound impairment of visual...

Bao-Yue Mi, Feng Jin, Jing-Qing Mu et al. · 0 citations
Case report Open access Oct 2026

Severe Pediatric Ocular Surface Disease: Multimodal Approach and Treatment

Background/Objectives: Pediatric ocular surface disease associated with ocular rosacea, chronic blepharitis and meibomian gland dysfunction may result in significant corneal morbidity. In refractory cases, the limitations of conventional therapy have stimulated interest in adjunctive treatment modalities, including int...

Laura Vilaverde, Bruno Ribeiro, Ricardo Parreira et al. · 0 citations
Review Oct 2026

Topical Tacrolimus in Ocular Disease: A Narrative Review of Mechanism of Action and Therapeutic Applications.

PURPOSE Immune-mediated inflammatory disorders of the ocular surface and anterior segment frequently require sustained immunosuppression, yet prolonged topical corticosteroid use carries the risk of glaucoma, cataract, and infection. Tacrolimus, a macrolide calcineurin inhibitor, has emerged as a steroid-sparing altern...

Hashem A. Abu Serhan, Salem Abu Al-Burak, L. Hassan et al. · 0 citations
Open access Sep 2026

Yiguanjian alleviates ocular surface inflammation and lacrimal gland immune dysregulation in experimental dry eye disease: evidence from in vivo and in vitro models

Background Persistent ocular surface inflammation and lacrimal gland immune dysregulation are central to the progression of dry eye disease (DED). Th17/Treg imbalance contributes to sustained inflammatory activation in the ocular surface and lacrimal gland. Yiguanjian (YGJ) has anti-inflammatory and immunomodulatory po...

Yuan Zhong, Jian Shi, Xi-Yuan Liu et al. · 0 citations
Review Open access Sep 2026

Ophthalmic Treatments and Evolving Management of Sjögren’s Disease: An Overview

Ophthalmic SjD management has evolved from palliative lubrication toward a stepwise, mechanism-directed paradigm integrating novel diagnostics, secretomotor stimulation, mechanical protection, and biologic disease modification; dedicated SjD-specific trials remain essential to validate these emerging interventions.

María García Forestier, José Nassar Badillo, Armando L. Oliver · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.